Rivaroxaban
CR012157
Phase 3 small_molecule completed
Quick answer
Rivaroxaban for Atrial Fibrillation is a Phase 3 program (small_molecule) at Johnson & Johnson Pharmaceutical Research & Development, L.L.C. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Indication
- Atrial Fibrillation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed